JP2023540444A5 - - Google Patents
Info
- Publication number
- JP2023540444A5 JP2023540444A5 JP2023507798A JP2023507798A JP2023540444A5 JP 2023540444 A5 JP2023540444 A5 JP 2023540444A5 JP 2023507798 A JP2023507798 A JP 2023507798A JP 2023507798 A JP2023507798 A JP 2023507798A JP 2023540444 A5 JP2023540444 A5 JP 2023540444A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cdr
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2012331.1 | 2020-08-07 | ||
| GBGB2012331.1A GB202012331D0 (en) | 2020-08-07 | 2020-08-07 | Therapeutic antibodies |
| PCT/GB2021/052043 WO2022029447A1 (en) | 2020-08-07 | 2021-08-06 | Therapeutic antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540444A JP2023540444A (ja) | 2023-09-25 |
| JP2023540444A5 true JP2023540444A5 (cg-RX-API-DMAC7.html) | 2026-02-02 |
Family
ID=72520053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507798A Pending JP2023540444A (ja) | 2020-08-07 | 2021-08-06 | 治療用抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230272097A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192867A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023540444A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116249710A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021319941A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186391A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202012331D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022029447A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| JP7671275B2 (ja) | 2019-08-29 | 2025-05-01 | エランコ・ユーエス・インコーポレイテッド | 動物用の抗il31抗体 |
| US20220332837A1 (en) * | 2021-04-08 | 2022-10-20 | Colorado State University Research Foundation | Methods and compositions for ox40 activation in treatment of canine cancer |
| WO2023152486A1 (en) * | 2022-02-09 | 2023-08-17 | Petmedix Ltd | Therapeutic antibodies |
| GB202217978D0 (en) * | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Rodents expressing a common light chain |
| KR20250137204A (ko) | 2022-12-27 | 2025-09-17 | 인베티엑스 인코포레이티드 | 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법 |
| CN121002059A (zh) | 2023-01-20 | 2025-11-21 | 因外泰克斯公司 | 用于伴侣动物的双特异性结合剂 |
| US20250257142A1 (en) * | 2024-02-13 | 2025-08-14 | Invetx, Inc. | Anti-il-31ra antibodies and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| CA2560889A1 (en) * | 2004-03-23 | 2005-10-13 | Sanjay D. Khare | Monoclonal antibodies specific for human ox40l (cd 134l) |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| US7812133B2 (en) * | 2005-12-16 | 2010-10-12 | Genentech, Inc | Anti-OX40L antibodies and methods using same |
| KR102119840B1 (ko) | 2011-07-11 | 2020-06-09 | 아이크노스 사이언스 에스. 아. | Ox40에 결합하는 항체 및 이들의 용도 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| EA032389B1 (ru) * | 2012-02-14 | 2019-05-31 | Мериал, Инк. | Рекомбинантные поксвирусные векторы, кодирующие и экспрессирующие гликопротеин g вируса бешенства и полипептид oxl, и вакцины, созданные на их основе, используемые в способе вакцинации животных против бешенства |
| GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| PL3265123T3 (pl) | 2015-03-03 | 2023-03-13 | Kymab Limited | Przeciwciała, zastosowania i sposoby |
| GB2561352B (en) | 2017-04-10 | 2023-01-18 | Genome Res Ltd | Animal models and therapeutic molecules |
| JP7449234B2 (ja) | 2018-03-16 | 2024-03-13 | ゾエティス・サービシーズ・エルエルシー | 獣医学使用のためのインターロイキン31モノクローナル抗体 |
| GB2578867A (en) | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
-
2020
- 2020-08-07 GB GBGB2012331.1A patent/GB202012331D0/en not_active Ceased
-
2021
- 2021-08-06 WO PCT/GB2021/052043 patent/WO2022029447A1/en not_active Ceased
- 2021-08-06 AU AU2021319941A patent/AU2021319941A1/en active Pending
- 2021-08-06 EP EP21758732.8A patent/EP4192867A1/en active Pending
- 2021-08-06 US US18/007,314 patent/US20230272097A1/en active Pending
- 2021-08-06 JP JP2023507798A patent/JP2023540444A/ja active Pending
- 2021-08-06 CA CA3186391A patent/CA3186391A1/en active Pending
- 2021-08-06 CN CN202180058009.6A patent/CN116249710A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250122301A1 (en) | Cd25 antibodies | |
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| Willems et al. | Rituximab therapy for childhood-onset systemic lupus erythematosus | |
| US10479830B2 (en) | Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines | |
| HUE034282T2 (en) | A monoclonal antibody to dog interleukin-31 | |
| RU2014121043A (ru) | Биспецифические иммуносвязывающие средства, направленные против tnf и il-17 | |
| CN109384844B (zh) | 一种抗金黄色葡萄球菌α溶血素单克隆抗体及应用 | |
| JP2017513813A5 (cg-RX-API-DMAC7.html) | ||
| JP2023540444A (ja) | 治療用抗体 | |
| WO2009140348A4 (en) | Anti-il-6/il-6r antibodies and methods of use thereof | |
| JP2017525655A5 (cg-RX-API-DMAC7.html) | ||
| WO2022117079A1 (zh) | 结合胸腺基质淋巴细胞生成素的抗体及其应用 | |
| JP2022527646A5 (cg-RX-API-DMAC7.html) | ||
| WO2005114218B1 (en) | Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule | |
| Hu et al. | Potential therapeutic strategies in chronic inflammatory demyelinating polyradiculoneuropathy | |
| JP2025506488A5 (cg-RX-API-DMAC7.html) | ||
| RU2024121576A (ru) | Терапевтические антитела | |
| US20240360210A1 (en) | Use of an il-18 antagonist for treating and/or prevention of atopic dermatitis or a related condition | |
| KR20230154239A (ko) | 항체-매개 이식 거부의 치료에 사용하기 위한 항-cd38 항체 | |
| CN118715244A (zh) | 治疗性抗体 | |
| JP2025506488A (ja) | 治療抗体 | |
| CN104391114B (zh) | Elisa方法定量测定人血清中重组人鼠嵌合抗cd20单克隆抗体浓度 | |
| RU2795411C2 (ru) | Моноклональные антитела к интерлейкину-31 для ветеринарного применения | |
| HK40063825A (en) | Cd25 antibodies | |
| NZ773527B2 (en) | Antibodies, uses & methods |